Literature DB >> 18545832

Serological reactivity of different antigenic preparations of Leishmania (Leishmania) amazonensis and the Leishmania braziliensis complex.

Adriano Gomes-Silva1, Maria Aparecida Souza, Sandra Regina Afonso-Cardoso, Lívia Resende Andrade, Reynaldo Dietze, Elenice Lemos, Alejandro Belli, Silvio Favoreto Júnior, Marcelo Simão Ferreira.   

Abstract

Total antigen from Leishmania (Leishmania) amazonensis and isolates from the Leishmania braziliensis complex, along with their respective antigenic fractions obtained by affinity chromatography on concanavalin-A-Sepharose and jacalin-agarose columns evaluated using immunoenzymatic ELISA assay. For this, serum samples from 229 patients were used, grouped as American tegmental leishmaniasis (n masculine=58), visceral leishmaniasis (n masculine=28), Chagas disease (n masculine=49), malaria (n masculine=32), tuberculosis (n masculine=13) and healthy volunteers (n masculine=49). Samples from American tegmentary leishmaniasis showed higher reactivity with antigens isolated from the Leishmania braziliensis complex than with antigens from Leishmania amazonensis (p<0.001). ELISA assays showed a sensitivity range from 60% to 95% with antigens isolated from the Leishmania braziliensis complex. There was marked nonspecific reactivity among serum samples with the use of antigenic fractions binding with concanavalin-A and jacalin from both Leishmania complexes, in comparison with other antigens (p<0.001). The results presented in this study suggest that the use of homologous antigens increases the efficiency of anti-Leishmania immunoglobulin detection, which may be very valuable for diagnostic purposes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18545832     DOI: 10.1590/s0037-86822008000200001

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  5 in total

1.  Immunoenzymatic assay for the diagnosis of American tegumentary leishmaniasis using soluble and membrane-enriched fractions from infectious Leishmania (Viannia) braziliensis.

Authors:  Jamyra Iglesias Cataldo; Fernanda Carvalho de Queiroz Mello; Eliame Mouta-Confort; Maria de Fátima Madeira; Armando de Oliveira Schubach; Marcelo da Silva Genestra; Flávia Coelho Ribeiro; Célia de Fátima Moreira-Venâncio; Sônia Regina Lambert Passos
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

2.  IgA detection in human neurocysticercosis using different preparations of heterologous antigen.

Authors:  Vanessa da S Ribeiro; Marianna N Manhani; Julia M Costa-Cruz
Journal:  Parasitol Res       Date:  2010-04-13       Impact factor: 2.289

3.  Comparative evaluation of lesion development, tissue damage, and cytokine expression in golden hamsters (Mesocricetus auratus) infected by inocula with different Leishmania (Viannia) braziliensis concentrations.

Authors:  Raquel P Ribeiro-Romão; Otacílio C Moreira; Elvia Yaneth Osorio; Lea Cysne-Finkelstein; Adriano Gomes-Silva; Joanna G Valverde; Claude Pirmez; Alda Maria Da-Cruz; Eduardo Fonseca Pinto
Journal:  Infect Immun       Date:  2014-10-06       Impact factor: 3.441

4.  A Cytokine Network Balance Influences the Fate of Leishmania (Viannia) braziliensis Infection in a Cutaneous Leishmaniasis Hamster Model.

Authors:  Milla B Paiva; Raquel Peralva Ribeiro-Romão; Larissa Resende-Vieira; Thais Braga-Gomes; Marcia P Oliveira; Andrea F Saavedra; Luzinei Silva-Couto; Hermano G Albuquerque; Otacilio C Moreira; Eduardo Fonseca Pinto; Alda Maria Da-Cruz; Adriano Gomes-Silva
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

5.  Field validation of a Leishmania (Leishmania) mexicana exo-antigens ELISA for diagnosing tegumentary leishmaniasis in regions of Leishmania (Viannia) predominance.

Authors:  Killarney Ataide Soares; Ada Amália Ayala Urdapilleta; Gilcilene Maria dos Santos; Andréa Lisboa Carneiro; Ciro Martins Gomes; Ana Maria Roselino; Raimunda Nonata Ribeiro Sampaio
Journal:  Braz J Infect Dis       Date:  2015-05-15       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.